589 |
Explore the Rationale for the Dual Mechanism CCB/ARB Approaches in Hypertension Management |
Jeong Bae Park |
Oct. 24. 08 |
588 |
Improving Outcomes in CV & Metabolic Disease, Landmark Trials Across the Continuum |
Dong-Ju Choi |
Oct. 24. 08 |
587 |
Triple Antiplatelet Therapy After DES Implantation in Patients with High Risk of Restenosis |
Seong-Wook Park |
Oct. 24. 08 |
586 |
Is Triple Anti-Platelet Therapy a Solution for Patients with Aspirin/Plavix Resistance ? |
Jung-Won Suh |
Oct. 24. 08 |
585 |
How Long Patients Will Be on Dual Antiplatelet Therapy? |
Ron Waksman |
Oct. 24. 08 |
584 |
Insights into Antiplatelet Therapy: From CAPRIE to TRITON-TIMI 38 |
Cheol Whan Lee |
Oct. 24. 08 |
583 |
TRIAS HR Pilot Study Long Term Follow-Up |
Robbert De Winter |
Oct. 24. 08 |
582 |
Endothelial Progenitor Cell Capture Technology and Beyond |
Michael Kutryk |
Oct. 24. 08 |
581 |
VH and OCT Clinical Experience and Future Perspective |
Gary S. Mintz |
Oct. 10. 08 |
580 |
Assessment of Vulnerable Plaque by OCT: Comparison Among Intravascular Imaging Modalities |
Takashi Akasaka |
Oct. 10. 08 |